Sweden’s Karo gains remaining Pevaryl rights

12 May 2020 - Deborah Wilkes


Sweden’s Karo Pharma has acquired the remaining European rights to the Pevaryl antifungal brand portfolio from Johnson & Johnson (J&J) for EUR58 million (USD63 million).

Click tags below for more information on topics:

Karo Pharma Johnson & Johnson COVID-19

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: